CorVista System with PH Add-On vs iCAC Device
AI Verdict
Choose CorVista System with PH Add-On if…
Choose the CorVista System with PH Add-On if you require a rapid, non-invasive, point-of-care diagnostic solution for both coronary artery disease and pulmonary hypertension. This tool is ideal for situations where avoiding radiation, contrast agents, or extensive patient preparation is critical, delivering results within minutes.
View CorVista System with PH Add-On →Choose iCAC Device if…
Choose the iCAC Device if you aim to opportunistically detect and quantify coronary artery calcium from routine, non-contrast chest CT scans already performed for other indications. This AI algorithm seamlessly integrates into radiology workflows to provide valuable adjunctive information for early cardiovascular disease risk assessment without requiring additional imaging.
View iCAC Device →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | CorVista System with PH Add-On | iCAC Device |
|---|---|---|
| Pricing | Contact for pricing | Contact for pricing |
| Deployment | Cloud-based (data collected at point-of-care, processed in the cloud, results via secure web portal). | Software as a Medical Device (SaMD), integrates with PACS or DICOM router. Cloud-based (via Carebricks platform). |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CorVista System with PH Add-OnCorVista System (Tool A) offers a non-invasive, point-of-care solution that provides rapid results within minutes, eliminating the need for radiation, contrast agents, injections, fasting, or exercise. Its 'iPad-sized interface' and ease of use by a medical assistant make it highly accessible and streamlined for both patients and clinical staff. In contrast, iCAC Device (Tool B) integrates into existing radiology workflows but still relies on CT scans, which involve radiation and more complex patient preparation.
Clinical Value
CorVista System with PH Add-OnCorVista System (Tool A) is FDA-cleared for direct diagnostic assessment of coronary artery disease (CAD) and pulmonary hypertension (PH), with strong clinical validation demonstrating high sensitivity and specificity for both conditions. It aims to significantly reduce diagnostic delays for symptomatic patients, particularly for PH where diagnosis can take years. While iCAC Device (Tool B) provides valuable opportunistic risk stratification by quantifying coronary artery calcium from existing CT scans, CorVista's direct diagnostic capability for actionable clinical decision-making offers a more immediate and impactful clinical utility.
Pricing & Value
CorVista System with PH Add-OnBoth tools require contacting the vendor for pricing. However, CorVista System (Tool A) explicitly operates on a 'medical-device-as-a-service' model and has published a cost economic analysis demonstrating its economic benefits and significant cost savings to the healthcare system by reducing the need for more expensive care and capital investment. This transparency regarding its value proposition gives it an advantage over iCAC Device (Tool B), for which no such economic details were found.
Enterprise Readiness
iCAC DeviceiCAC Device (Tool B) explicitly highlights its integration capabilities with PACS, DICOM routers, and EHRs via the Carebricks platform, which are essential for seamless adoption within existing hospital and radiology department workflows. While CorVista System (Tool A) is cloud-based and accessible via a secure web portal, its broader integration with hospital IT infrastructure is not as clearly articulated in the provided information.
Innovation
CorVista System with PH Add-OnCorVista System (Tool A) represents a significant innovation by offering a completely non-invasive, point-of-care AI diagnostic platform for complex cardiovascular conditions like CAD and PH, eliminating traditional diagnostic burdens such as radiation, contrast agents, and extensive patient preparation. This approach fundamentally transforms the diagnostic pathway. While iCAC Device (Tool B) innovates by leveraging existing CT scans for opportunistic CAC detection, CorVista's method is a more disruptive advancement in diagnostic methodology.
Support & Docs
TieNeither the provided structured facts nor the web search results offered specific details regarding the level of customer support, available documentation, training programs, or service level agreements for either CorVista System (Tool A) or iCAC Device (Tool B). Therefore, it is not possible to distinguish between the two tools on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | CorVista System with PH Add-On | iCAC Device |
|---|---|---|
| Tool Name | CorVista System with PH Add-On | iCAC Device |
| Company | Analytics for Life | Bunkerhill Health |
| Primary Diagnostic Focus | Rapid assessment of coronary artery disease and pulmonary hypertension. | Detects and quantifies coronary artery calcium from routine, non-contrast, non-gated chest CT scans, aiding in early cardiovascular disease detection. |
| Input Data/Method | Analyzes cardiac and hemodynamic signals; no radiation, contrast agents, injections, fasting, or exercise required. | Analyzes routine, non-contrast, non-gated chest CT scans. |
| Algorithm Type | Machine-learned algorithms | Deep-learning algorithms |
| Key Output/Result | Rapid results available within minutes via secure web portal for physician access to analysis. | Estimates presence and quantity of coronary artery calcium (CAC), outputs visual representation of estimated CAC segmentation, delivers exact and four-category quantitative estimates of CAC burden in Agatston units. |
Videos
Demos, reviews, and walkthroughs featuring CorVista System with PH Add-On and iCAC Device.